🔎 Trials Near Me

Dachaigh › Aillse Sgamhain Neo-chealla-beag › Delaware › Newark

Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Newark, DE

Tha 16 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Newark (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

A’ fastadhÌre 3
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A’ fastadhÌre 1/2
  • Medical Oncology Hematology Consultants, Newark
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

A’ fastadhÌre 3
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07388524

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A’ fastadhÌre 3
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A’ fastadhÌre 3
  • Medical Oncology Hematology Consultants, PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07361497

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

A’ fastadhÌre 3
  • Medical Oncology Hematology Consultants, PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07144280

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

A’ fastadhÌre 3
  • Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A’ fastadhÌre 2
  • ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

A’ fastadhÌre 2
  • ChristianaCare Health System, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07154290

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

A’ fastadhÌre 3
  • Research Site, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06868277

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A’ fastadhÌre 3
  • Medical Oncology Hematology Consultants, PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06875310

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

A’ fastadhÌre 3
  • Research Site, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT06692738

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

A’ fastadhÌre 3
  • Research Site, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07291037

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

A’ fastadhÌre 2/3
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Cèit 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

A’ fastadhSgrùdadh amharc
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
  • Christiana Care - Union Hospital, Elkton · 7 mìle air falbh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Màrt 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

A’ fastadhSgrùdadh amharc
  • Massive Bio SYNERGY-AI site, Newark
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile

Sgrùdaidhean eile ann an Newark

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.